Protalix BioTherapeutics
PLX
38 hedge funds and large institutions have $8.2M invested in Protalix BioTherapeutics in 2018 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 5 closing their positions.
141% more capital invested
Capital invested by funds: $3.4M → $8.2M (+$4.8M)
67% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 6
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
6% more funds holding
Funds holding: 36 → 38 (+2)
0.22% more ownership
Funds ownership: 0.54% → 0.77% (+0.22%)
90% less call options, than puts
Call options by funds: $23K | Put options by funds: $233K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FI
Fosun International
Hong Kong,
China
|
+$1.32M |
| 2 |
Renaissance Technologies
New York
|
+$327K |
| 3 |
EMG
ETF Managers Group
Summit,
New Jersey
|
+$166K |
| 4 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$108K |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$50K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$301K |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$30.3K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$29.7K |
| 4 |
Morgan Stanley
New York
|
-$14.8K |
| 5 |
Goldman Sachs
New York
|
-$12K |
PLX Hedge Fund Activity: Q3 2018 in Review
38 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q3 2018, worth a combined $8.2M — up 141% from $3.4M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new PLX positions and 5 closed out — a net gain of 2 holders — while 10 added to existing stakes and 6 trimmed.
The largest buyer was Fosun International, opening a new position worth an estimated $1.32M. The largest seller was Opaleye Management, cutting an estimated $301K.
- 38 institutional investors held Protalix BioTherapeutics (PLX) as of Q3 2018, up from 36 in Q2 2018.
- Funds reported $8.2M of Protalix BioTherapeutics stock for Q3 2018, up 141% quarter-over-quarter.
- 7 funds opened new Protalix BioTherapeutics positions in Q3 2018 and 5 closed out, a net change of +2 holders.
- The largest Protalix BioTherapeutics buyer in Q3 2018 was Fosun International, an estimated $1.32M added.
- The largest Protalix BioTherapeutics seller in Q3 2018 was Opaleye Management, an estimated $301K sold.
Based on aggregated 13F filings for Q3 2018.